Pharmacogenetics, Emotional Reactivity and Smoking

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

646

Participants

Timeline

Start Date

December 8, 2005

Primary Completion Date

December 18, 2019

Study Completion Date

December 18, 2019

Conditions
Tobacco Use DisorderSmoking Cessation
Interventions
DRUG

Bupropion

Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)

DRUG

Varenicline

Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)

DRUG

Placebo

Placebo by mouth for 12 weeks.

BEHAVIORAL

Smoking Cessation Counseling

Counseling over 8 months and telephone support calls.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00507728 - Pharmacogenetics, Emotional Reactivity and Smoking | Biotech Hunter | Biotech Hunter